SCRS Welcomes GlaxoSmithKline as a Global Impact Partner
Ellicott City, MD – The Society for Clinical Research Sites (SCRS) announces GSK as a Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
GSK was a finalist for the 2016 SCRS Eagle Award honoring clinical research sponsors and CROs which are highly ranked by sites.
“GSK’s commitment to the sites through their collaboration with SCRS is a strong signal of the value they see in sites having a unified voice and wanting to be part of that dialogue and community,” said SCRS President, Christine Pierre. “We look forward to ongoing collaboration with GSK to ensure they benefit from the value of the SCRS community as well, which ultimately will strengthen the sponsor and site partnership.”
Anne Marie Inglis, Head of US Clinical Operations, GSK comments “We believe the support and continued development of investigational sites is a key component in clinical trial success. As the individuals actually working daily with clinical trial subjects, investigational sites offer keen insight into improving the clinical trial experience. The SCRS network offers GSK an opportunity to build stronger relationships with the site community and work together to enhance the conduct of clinical trials.”
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About GlaxoSmithKline
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
